Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
139 hedge funds and large institutions have $377M invested in Catalyst Pharmaceutical in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 56 reducing their positions, and 16 closing their positions.
44% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 16
21% more capital invested
Capital invested by funds: $312M → $377M (+$64.7M)
5% more funds holding
Funds holding: 133 → 139 (+6)
1.82% less ownership
Funds ownership: 65.2% → 63.38% (-1.8%)
29% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 56
75% less call options, than puts
Call options by funds: $634K | Put options by funds: $2.57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$14.6M |
| 2 |
JP Morgan Chase
New York
|
+$4.04M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$3.4M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.56M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$15.1M |
| 2 |
Prudential Financial
Newark,
New Jersey
|
-$4.23M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$3.54M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.1M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.06M |
CPRX Hedge Fund Activity: Q2 2021 in Review
139 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2021, worth a combined $377M — up 21% from $312M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CPRX positions and 16 closed out — a net gain of 7 holders — while 40 added to existing stakes and 56 trimmed.
The largest buyer was LSV Asset Management, adding an estimated $14.6M. The largest seller was State Street, cutting an estimated $15.1M.
- 139 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2021, up from 133 in Q1 2021.
- Funds reported $377M of Catalyst Pharmaceutical stock for Q2 2021, up 21% quarter-over-quarter.
- 23 funds opened new Catalyst Pharmaceutical positions in Q2 2021 and 16 closed out, a net change of +7 holders.
- The largest Catalyst Pharmaceutical buyer in Q2 2021 was LSV Asset Management, an estimated $14.6M added.
- The largest Catalyst Pharmaceutical seller in Q2 2021 was State Street, an estimated $15.1M sold.
Based on aggregated 13F filings for Q2 2021.